LONDON – A study from the University of Oxford found that the number of people who get blood clots after being vaccinated with a coronavirus vaccine is about the same for those who get Pfizer and Moderna as those who are vaccinated with AstraZeneca.
According to the study, 4 in 1 million people experience cerebral vein thrombosis (CVT) after receiving the Pfizer or Moderna vaccine, compared to 5 in 1 million people with the AstraZeneca vaccine.
The risk of CVT is much higher for those who receive Covid-19 (39 in a million patients) than for those who are vaccinated.
Use of the AstraZeneca vaccine has been discontinued or restricted in many countries due to blood clot problems.
The risk of cerebral vein thrombosis, forcing many regulators to discontinue or discontinue the use of AstraZeneca and J&J vaccines, seems very to be comparable. pic.twitter.com/KZcMCIQVXd
– Sputnik V (@sputnikvaccine)
April 16, 2021
The broken down comparison of reported CVT cases in Covid-19 patients compared to CVT cases in those who received a Covid-19 vaccine is:
In this study of more than 500,000 patients with Covid-19, CVT occurred in 39 of the million patients.
In more than 480,000 people who received an mRNA vaccine against Covid-19 (Pfizer or Moderna), TVC occurred in 4 in a million.
TVC has been reported in about 5 in million people after the first dose of the AstraZeneca vaccine.
Compared to mRNA vaccines, the risk of a Covid-19 CVT is about 10 times higher.
Compared to the AstraZeneca vaccine, the risk of a Covid-19 CVT is about 8 times higher.
However, they requested that all comparisons be interpreted with caution as the data is still being analyzed.
Finally:
The risk of CVT after the first dose of AstraZeneca is 5 in million people vaccinated; that of having a cerebral venous thrombosis after a Pfizer or Moderna vaccine is 4 in a million; that of this rare thrombus in patients with covid, 39 in every million. The study envisaged 513,284 patients infected with the coronavirus and 489,871 with a messenger RNA vaccine (Pfizer or Moderna). AstraZeneca’s risk data is as described by the EMA.